326 related articles for article (PubMed ID: 28364396)
1. Interleukin-5 Inhibitors for Severe Asthma: Rationale and Future Outlook.
Shrimanker R; Pavord ID
BioDrugs; 2017 Apr; 31(2):93-103. PubMed ID: 28364396
[TBL] [Abstract][Full Text] [Related]
2. Treatment Challenges in Severe Eosinophilic Asthma: Differential Response to Anti-IL-5 and Anti-IL-5R Therapy.
Bakakos A; Rovina N; Bakakos P
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33921360
[TBL] [Abstract][Full Text] [Related]
3. Evidence for the efficacy and safety of anti-interleukin-5 treatment in the management of refractory eosinophilic asthma.
Hilvering B; Xue L; Pavord ID
Ther Adv Respir Dis; 2015 Aug; 9(4):135-45. PubMed ID: 25900924
[TBL] [Abstract][Full Text] [Related]
4. Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab.
Pelaia C; Vatrella A; Busceti MT; Gallelli L; Terracciano R; Savino R; Pelaia G
Drug Des Devel Ther; 2017; 11():3137-3144. PubMed ID: 29133975
[TBL] [Abstract][Full Text] [Related]
5. Exacerbations of Severe Asthma While on Anti-IL-5 Biologics.
Bhalla A; Zhao N; Rivas DD; Ho T; Perez de Llano L; Mukherjee M; Nair P
J Investig Allergol Clin Immunol; 2020; 30(5):307-316. PubMed ID: 32573459
[TBL] [Abstract][Full Text] [Related]
6. Mepolizumab in the treatment of severe eosinophilic asthma.
Fainardi V; Pisi G; Chetta A
Immunotherapy; 2016; 8(1):27-34. PubMed ID: 26653083
[TBL] [Abstract][Full Text] [Related]
7. Mepolizumab: First Global Approval.
Keating GM
Drugs; 2015 Dec; 75(18):2163-9. PubMed ID: 26603873
[TBL] [Abstract][Full Text] [Related]
8. [Benralizumab: Targeting the IL-5 Receptor in Severe Eosinophilic Asthma].
Leuppi JD; Schmid-Grendelmeier P; Rothe T; von Garnier C; Simon HU; Schuoler C; Pendl G; Solèr M
Praxis (Bern 1994); 2019; 108(7):469-476. PubMed ID: 31136272
[TBL] [Abstract][Full Text] [Related]
9. [Treatment of refractory asthma with antibodies].
Lommatzsch M
Dtsch Med Wochenschr; 2016 Jun; 141(11):790-3. PubMed ID: 27254629
[TBL] [Abstract][Full Text] [Related]
10. [Benralizumab: Targeting the IL-5 Receptor in Severe Eosinophilic Asthma].
Leuppi JD; Schmid-Grendelmeier P; Rothe T; von Garnier C; Simon HU; Schuoler C; Pendl G; Solèr M
Praxis (Bern 1994); 2019; 108(7):1-8. PubMed ID: 31136278
[TBL] [Abstract][Full Text] [Related]
11. Eosinophils and interleukin-5: the debate continues.
Kay AB; Menzies-Gow A
Am J Respir Crit Care Med; 2003 Jun; 167(12):1586-7. PubMed ID: 12796050
[No Abstract] [Full Text] [Related]
12. Pharmacokinetic/pharmacodynamic drug evaluation of benralizumab for the treatment of asthma.
Matera MG; Calzetta L; Rinaldi B; Cazzola M
Expert Opin Drug Metab Toxicol; 2017 Sep; 13(9):1007-1013. PubMed ID: 28737051
[TBL] [Abstract][Full Text] [Related]
13. Overlapping Effects of New Monoclonal Antibodies for Severe Asthma.
Domingo C
Drugs; 2017 Oct; 77(16):1769-1787. PubMed ID: 28948572
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic/pharmacodynamic profile of reslizumab in asthma.
Matera MG; Rogliani P; Calzetta L; Cazzola M
Expert Opin Drug Metab Toxicol; 2018 Feb; 14(2):239-245. PubMed ID: 29268638
[TBL] [Abstract][Full Text] [Related]
15. Matching-adjusted indirect comparison of benralizumab
Bourdin A; Husereau D; Molinari N; Golam S; Siddiqui MK; Lindner L; Xu X
Eur Respir J; 2018 Nov; 52(5):. PubMed ID: 30309978
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic drug evaluation of mepolizumab for the treatment of severe asthma associated with persistent eosinophilic inflammation in adults.
Kallur L; Gonzalez-Estrada A; Eidelman F; Dimov V
Expert Opin Drug Metab Toxicol; 2017 Dec; 13(12):1275-1280. PubMed ID: 29157020
[TBL] [Abstract][Full Text] [Related]
17. Safety of humanized monoclonal antibodies against IL-5 in asthma: focus on reslizumab.
Cazzola M; Matera MG; Levi-Schaffer F; Rogliani P
Expert Opin Drug Saf; 2018 Apr; 17(4):429-435. PubMed ID: 29486600
[TBL] [Abstract][Full Text] [Related]
18. Controversies in Allergy: Should Severe Asthma with Eosinophilic Phenotype Always Be Treated with Anti-IL-5 Therapies.
Pavord ID; Hanania NA
J Allergy Clin Immunol Pract; 2019; 7(5):1430-1436. PubMed ID: 30962155
[No Abstract] [Full Text] [Related]
19. Forced oscillation technique as method to document and monitor the efficacy of mepolizumab in treating severe eosinophilic asthma.
Antonicelli L; Tontini C; Marchionni A; Lucchetti B; Garritani MS; Bilò MB
Allergy; 2020 Feb; 75(2):433-436. PubMed ID: 31166020
[No Abstract] [Full Text] [Related]
20. Benralizumab for the add-on maintenance treatment of patients with severe asthma aged 12 years and older with an eosinophilic phenotype.
Al Efraij K; FitzGerald JM
Expert Rev Clin Pharmacol; 2018 Jul; 11(7):669-676. PubMed ID: 29972739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
